DIA  DEEP  DIVE:  The  Drug  Pricing  Conundrum
As the most expensive drug ever to be developed gets approved and patients and insurers face a seven-figure price tag, some argue that the drug is easily worth the money. At $2.1 million, Novartis’ new gene therapy promises to treat spinal muscular atrophy (SMA), a rare childhood disorder, in just a single treatment.

Video Interview

Value-Based Contracting and Assessment: What Needs to be Done to Make it a Best Practice? Michael Rosenblatt, Flagship Pioneering
Watch More

Want to learn more?

DIA 2019At our upcoming DIA 2019 Global Annual Meeting, check out the session on Public and Regulatory Response To Drug Pricing Concerns, or attend our Regulatory, Value and Access Strategy Workshop in Basel.

No time to travel? Check out our on-demand course on Biosimilar Reimbursement in the US Marketplace.
Member-only contentMember-only content